# On-target validation of drug effects

Source: https://onco.cc/terms/on-target-drug-validation/  
OnCo record `on-target-drug-validation` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A drug can change cell behavior through a different target from the one proposed. Complementary experiments help establish which mechanism actually caused the effect.

## Summary

Primary genetic interrogation of selected cancer drugs found examples in which cell-killing activity persisted after loss of the proposed target. The study illustrates why pharmacological response alone is insufficient to establish a cancer dependency. Genetic perturbation, complementary compounds, suitable controls and target-engagement measurements address different parts of the claim. Agreement strengthens a mechanism within the tested system; it does not establish a safe or effective treatment in people.

## Fields

- Kind: Term
- Last checked: 2026-11-11
- Also known as: on-target versus off-target drug effects; genetic validation of drug mechanism

## Notes

- Controls and their limits. In chemical-probe practice an inactive close analogue serves as a negative control and a second, structurally unrelated probe reduces the chance of shared off-targets (Arrowsmith et al. 2015). Genetic perturbation is a separate line of evidence, with its own limit: removing a whole protein can differ from inhibiting one of its functions (the teaching lesson's reasoning, not a result read). The nearest real example is natural reversion: ovarian cancer lines from one BRCA2 mutation carrier acquired a secondary BRCA2 mutation that restored BRCA2 and went with resistance to cisplatin and a PARP inhibitor, and transient siRNA depletion of BRCA2 re-sensitised the restored clones (Sakai et al. 2009); that is natural reversion plus knockdown in one patient's lineage, and depletion is not pharmacological inhibition. Agreement among controls supports a mechanism in the tested system only.
- What to do next with a viability result. If a compound lowers viability in culture at one concentration, measure engagement and relevant selectivity, compare an inactive analogue and an independent probe, and use a suitable genetic perturbation or rescue; exposure, product quality, safety and clinical evidence remain separate questions that controls do not settle.

## Sources

- Genetic validation of proposed cancer-drug targets (2019): https://doi.org/10.1126/scitranslmed.aaw8412
- Workman and Collins, fit-for-purpose chemical probes (2010): https://pubmed.ncbi.nlm.nih.gov/20609406/
- Arrowsmith et al., chemical-probe quality and controls (2015): https://pubmed.ncbi.nlm.nih.gov/26196764/
- Sakai et al., BRCA2 restoration and acquired resistance (2009): https://pubmed.ncbi.nlm.nih.gov/19654294/

## Connected records

- terms: [Copy-number artifacts in gene-dependency screens](https://onco.cc/terms/crispr-copy-number-artifact/), [Drug target engagement](https://onco.cc/terms/drug-target-engagement/), [Evidence from measurement to patient benefit](https://onco.cc/terms/measurement-to-benefit-evidence/), [Functional evidence for a sequence variant](https://onco.cc/terms/functional-variant-evidence/)
- technologies: [CRISPR functional genomics](https://onco.cc/technologies/crispr-screens/)

---
JSON: https://onco.cc/api/v1/entities/on-target-drug-validation.json